Core Insights - The company is focused on transforming into an innovative oncology firm that aims to overcome immune resistance in cancer treatment [3] Company Progress - The CEO provided an update on the company's progress over the past 12 months since the last conference [2] - The cornerstone therapy for the company is LOQTORZI, which serves as a revenue multiplier in conjunction with their PD-1 backbone [3] Promising Assets - The company is developing Tagmokitug, a promising asset in the evolving class of Treg depleters, highlighting its mechanism of action and potential as a new treatment paradigm [3] - Casdozokitug was also mentioned as part of the company's portfolio, indicating ongoing development in innovative cancer therapies [3]

Coherus Oncology FY Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Event**: FY Conference at the 44th JPMorgan Healthcare Conference - **Date**: January 13, 2026 Key Points Company Transformation and Strategy - Coherus has evolved into an innovative oncology company focused on overcoming immune resistance in cancer treatment, with Lactose as a cornerstone therapy [2][3] - The acquisition of Surface Oncology in September 2023 provided global rights to promising products CHS-114 (a CCR8 Treg depleter) and Casdozokitug [4] - The company divested its biosimilar business, raising approximately $800 million, which helped pay down $480 million in debt and support ongoing clinical studies [5] Product Pipeline and Market Opportunities - Coherus's pipeline represents a market opportunity of approximately $29 billion, with significant potential in both U.S. and ex-U.S. markets [9] - **Lactose**: A next-generation PD-1 therapy showing high activity, particularly in low PD-1 states, with a five-year survival rate improvement from 34 months to 65 months when combined with chemotherapy [11] - **CHS-114**: Positioned as a best-in-class Treg depleter, targeting Tregs in the tumor microenvironment to enhance T cell infiltration [15][16] - **Casdozokitug**: A first-in-class IL-27 antagonist showing a 38% overall response rate in hepatocellular carcinoma (HCC) studies, with ongoing trials expected to yield data in mid-2026 [24][25] Financial Projections and Sales Growth - Coherus anticipates revenue growth for Lactose, projecting $150-$200 million by mid-2028, supported by a strong sales trajectory and market penetration strategies [12][49] - The company has successfully increased demand growth quarter-over-quarter, exceeding initial guidance of 10%-15% [12] Clinical Trials and Data Expectations - Coherus is conducting multiple clinical trials across various cancers, with significant data readouts expected in 2026 [6][19] - The company is focused on optimizing dosing and understanding the best treatment settings for its products, particularly for Tecmo Kito and Casdozokitug [31][32] Competitive Landscape and Differentiation - Coherus emphasizes the selectivity and potency of its products, particularly Tecmo Kito, which is the only selective CCR8 binder disclosed, differentiating it from competitors [33][34] - The company is pursuing partnerships to enhance the development of its therapies, particularly in combination with other modalities like T-cell engagers and CAR-T therapies [40][41] Challenges and Market Dynamics - The company faces challenges in educating community physicians about its products due to the rarity of the diseases treated, necessitating sophisticated outreach strategies [48][49] - Coherus is aware of the competitive landscape and is strategically positioning its products to overcome resistance mechanisms in solid tumors [43] Future Outlook - Coherus is optimistic about 2026, with a strong focus on data generation and strategic partnerships to drive growth and enhance shareholder value [29][30] Conclusion Coherus Oncology is strategically positioned for growth in the oncology market with a robust pipeline and a focus on innovative therapies. The company is actively working to enhance its market presence and drive shareholder value through strategic partnerships and clinical advancements.

Core Insights - Coherus Oncology, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time, with the presentation accessible via webcast [1] - The webcast will be available for replay until February 13, 2026 [2] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting various cancers [3] - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advancing new indications for LOQTORZI in combination with its pipeline candidates and partners [3] Pipeline Details - Coherus' oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [4] - Tagmokitug, a selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]

Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [3] - The company has a pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, head & neck, and colorectal [3] Upcoming Events - Senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time [1] - The presentation and Q&A session will be accessible via webcast, available for replay until February 13, 2026 [1][2] Pipeline and Research - Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [4] - Tagmokitug, a highly selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]

Core Viewpoint - Coherus Oncology has introduced its investigational anti-CCR8 monoclonal antibody, tagmokitug, which shows high selectivity and efficacy in targeting CCR8+ T regulatory cells in solid tumors, indicating its potential as an anticancer treatment [1][3][4]. Group 1: Scientific Evidence and Mechanism - The publication in Molecular Cancer Therapeutics highlights tagmokitug's picomolar binding affinity and its ability to selectively eliminate CCR8+ T regulatory cells without off-target binding [1][3]. - Preclinical and clinical studies demonstrate that tagmokitug induces significant tumor regression in mouse models, especially when combined with anti-PD-1 antibody treatment [4]. - The first-in-human clinical study confirms that tagmokitug leads to selective reductions in CCR8+ Tregs in cancer patients, establishing proof of mechanism [5]. Group 2: Clinical Development and Pipeline - Tagmokitug is currently undergoing Phase 1b/2a clinical trials in combination with the PD-1 inhibitor toripalimab and chemotherapy for patients with various solid tumors [6][8]. - Coherus Oncology's pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [8]. Group 3: Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline targeting various cancers [7]. - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with its pipeline candidates [7].

Core Insights - Coherus Oncology's CHS-114 shows promising results in selectively depleting CCR8+ Tregs and enhancing immune response in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) [1][2][3] Clinical Trial Results - The Phase 1b clinical trial of CHS-114 demonstrated a greater than 50% increase in intratumoral CD8 T cells, indicating a shift towards a "hot" tumor microenvironment [1][2] - CHS-114 treatment resulted in a 74% reduction in CCR8+ Treg density and a 73% increase in CD8+ T cell density, showcasing effective immune remodeling [5][6] Safety and Efficacy - The combination of CHS-114 with toripalimab has shown a manageable safety profile and early signs of antitumor activity in HNSCC patients [2][3] - A partial response was observed in a refractory head and neck cancer patient during initial safety testing of the combination therapy [3] Development Strategy - The data supports advancing CHS-114 in combination with toripalimab or other immune activators, aligning with the company's development plan [3][4] - Ongoing enrollment in the dose optimization arm aims to address the FDA's Project Optimus and define a phase 2 dose for CHS-114 [3][7] Company Overview - Coherus Oncology is focused on developing innovative oncology therapies, including the next-generation PD-1 inhibitor LOQTORZI and CHS-114, targeting various cancers [9][10]

Core Insights - Coherus Oncology, Inc. will release its third quarter 2025 financial results on November 6, 2025, after market close [1] - A conference call and webcast will be held at 5:00 p.m. Eastern Time on the same day to discuss the financial results and provide a business update [1][3] Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a growing revenue stream [6] - The company has a promising pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [6] Pipeline and Research - Coherus' pipeline features multiple antibody immunotherapy candidates aimed at enhancing immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors [7] - Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [7]

Core Insights - Coherus Oncology is set to present CHS-114, an anti-CCR8 cytolytic antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5-9, 2025 [1][2] - CHS-114 has shown selective intratumoral Treg depletion and favorable immune remodeling in patients with advanced solid tumors [2] - The company is focused on enhancing its immuno-oncology pipeline, which includes multiple antibody candidates aimed at improving patient outcomes in cancer treatment [4] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a promising proprietary pipeline [3] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and explore new indications in combination with its pipeline candidates and partners [3] - Coherus' pipeline includes candidates targeting various cancers, including liver, lung, head & neck, colorectal, gastric, and esophageal cancers [4] Upcoming Events - CHS-114 will be featured in a live webinar series titled "Targets for Cancer IO: A Deep Dive" on October 22, 2025, discussing the therapeutic target CCR8 and its implications in cancer treatment [2][8] - The webinar will include discussions on the mechanisms and clinical results of anti-CCR8 antibodies, highlighting the latest advances in this area [2]

Coherus BioSciences FY Conference Summary Company Overview - Coherus BioSciences has transitioned from a biosimilar company to a full immuno-oncology (IO) company, divesting its biosimilar business over the past year and acquiring Surface Oncology in 2023, which added key assets CHS-114 and Casdozokitug to its pipeline [4][6] Core Strategies and Differentiation - The company focuses on combining its PD-1 agent, Toripalimab, with other agents like CHS-114 and Casdozokitug to enhance patient outcomes in various cancers [5][6] - Coherus emphasizes partnerships and collaborations, aiming to validate its platform, generate income, and share costs for pivotal trials [6][7] - The company plans to focus on ex-U.S. partnerships and licensing, with global rights to its assets acquired through recent acquisitions [6][8] Product Performance and Market Position - LOQTORZI, the company's product, has been positioned at the top of NCCN guidelines, leading to a 36% increase in utilization from Q1 to Q2 2025 [12] - The company anticipates reaching $150 to $200 million in revenue by mid-2028, although early adoption may be uneven due to the nature of the patient population [12][13] - 90% of NCCN institutions have ordered LOQTORZI, indicating strong performance in academic centers, while community settings require more educational efforts [14][15] Pipeline Developments - Casdozokitug, an IL-27 antagonist, is in a phase 2 study for first-line HCC, showing promising early responses and safety profiles [16][18] - CHS-114, a CCR8 antibody, is in several phase 1 studies, targeting T-regs in solid tumors, with early data showing immune activation and robust T-reg depletion [22][23] Competitive Landscape and Market Dynamics - The company does not foresee significant impact from the potential loss of exclusivity for Keytruda, as its products are differentiated and will not be directly affected by biosimilars [25][26] - Coherus is positioned to collaborate with other biotechs, especially in underserved tumor types, enhancing its development capabilities [28] Future Milestones - Upcoming milestones include top-line results from the HCC study on Casdozokitug and further progression of CHS-114 in head and neck and gastric cancers [33] - The company expects to pursue transactions to offset development costs and anticipates earnout payments from its partner Accord Healthcare, which has gained significant market share [34]

Company Overview - Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [4] - The company has a growing revenue stream and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, and head & neck [4] Product and Pipeline - LOQTORZI is being positioned to grow sales in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [4] - The immuno-oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [5] - Casdozokitug, a novel IL-27 antagonistic antibody, is currently in multiple Phase 1/2 and Phase 2 studies for advanced solid tumors, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [5] - CHS-114, a selective cytolytic anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC), gastric cancer, and esophageal cancer [5] Upcoming Events - Coherus will be participating in several upcoming conferences, including the Baird 2025 Global Healthcare Conference on September 9, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [6] - A virtual event, UBS Virtual Oncology Day, is scheduled for October 1, 2025 [6] - Presentations will be accessible via webcast, with replays available for 30 days [1]